Cargando…

Explainable deep drug–target representations for binding affinity prediction

BACKGROUND: Several computational advances have been achieved in the drug discovery field, promoting the identification of novel drug–target interactions and new leads. However, most of these methodologies have been overlooking the importance of providing explanations to the decision-making process...

Descripción completa

Detalles Bibliográficos
Autores principales: Monteiro, Nelson R. C., Simões, Carlos J. V., Ávila, Henrique V., Abbasi, Maryam, Oliveira, José L., Arrais, Joel P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204982/
https://www.ncbi.nlm.nih.gov/pubmed/35715734
http://dx.doi.org/10.1186/s12859-022-04767-y
_version_ 1784729034020618240
author Monteiro, Nelson R. C.
Simões, Carlos J. V.
Ávila, Henrique V.
Abbasi, Maryam
Oliveira, José L.
Arrais, Joel P.
author_facet Monteiro, Nelson R. C.
Simões, Carlos J. V.
Ávila, Henrique V.
Abbasi, Maryam
Oliveira, José L.
Arrais, Joel P.
author_sort Monteiro, Nelson R. C.
collection PubMed
description BACKGROUND: Several computational advances have been achieved in the drug discovery field, promoting the identification of novel drug–target interactions and new leads. However, most of these methodologies have been overlooking the importance of providing explanations to the decision-making process of deep learning architectures. In this research study, we explore the reliability of convolutional neural networks (CNNs) at identifying relevant regions for binding, specifically binding sites and motifs, and the significance of the deep representations extracted by providing explanations to the model’s decisions based on the identification of the input regions that contributed the most to the prediction. We make use of an end-to-end deep learning architecture to predict binding affinity, where CNNs are exploited in their capacity to automatically identify and extract discriminating deep representations from 1D sequential and structural data. RESULTS: The results demonstrate the effectiveness of the deep representations extracted from CNNs in the prediction of drug–target interactions. CNNs were found to identify and extract features from regions relevant for the interaction, where the weight associated with these spots was in the range of those with the highest positive influence given by the CNNs in the prediction. The end-to-end deep learning model achieved the highest performance both in the prediction of the binding affinity and on the ability to correctly distinguish the interaction strength rank order when compared to baseline approaches. CONCLUSIONS: This research study validates the potential applicability of an end-to-end deep learning architecture in the context of drug discovery beyond the confined space of proteins and ligands with determined 3D structure. Furthermore, it shows the reliability of the deep representations extracted from the CNNs by providing explainability to the decision-making process. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12859-022-04767-y.
format Online
Article
Text
id pubmed-9204982
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-92049822022-06-18 Explainable deep drug–target representations for binding affinity prediction Monteiro, Nelson R. C. Simões, Carlos J. V. Ávila, Henrique V. Abbasi, Maryam Oliveira, José L. Arrais, Joel P. BMC Bioinformatics Research BACKGROUND: Several computational advances have been achieved in the drug discovery field, promoting the identification of novel drug–target interactions and new leads. However, most of these methodologies have been overlooking the importance of providing explanations to the decision-making process of deep learning architectures. In this research study, we explore the reliability of convolutional neural networks (CNNs) at identifying relevant regions for binding, specifically binding sites and motifs, and the significance of the deep representations extracted by providing explanations to the model’s decisions based on the identification of the input regions that contributed the most to the prediction. We make use of an end-to-end deep learning architecture to predict binding affinity, where CNNs are exploited in their capacity to automatically identify and extract discriminating deep representations from 1D sequential and structural data. RESULTS: The results demonstrate the effectiveness of the deep representations extracted from CNNs in the prediction of drug–target interactions. CNNs were found to identify and extract features from regions relevant for the interaction, where the weight associated with these spots was in the range of those with the highest positive influence given by the CNNs in the prediction. The end-to-end deep learning model achieved the highest performance both in the prediction of the binding affinity and on the ability to correctly distinguish the interaction strength rank order when compared to baseline approaches. CONCLUSIONS: This research study validates the potential applicability of an end-to-end deep learning architecture in the context of drug discovery beyond the confined space of proteins and ligands with determined 3D structure. Furthermore, it shows the reliability of the deep representations extracted from the CNNs by providing explainability to the decision-making process. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12859-022-04767-y. BioMed Central 2022-06-17 /pmc/articles/PMC9204982/ /pubmed/35715734 http://dx.doi.org/10.1186/s12859-022-04767-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Monteiro, Nelson R. C.
Simões, Carlos J. V.
Ávila, Henrique V.
Abbasi, Maryam
Oliveira, José L.
Arrais, Joel P.
Explainable deep drug–target representations for binding affinity prediction
title Explainable deep drug–target representations for binding affinity prediction
title_full Explainable deep drug–target representations for binding affinity prediction
title_fullStr Explainable deep drug–target representations for binding affinity prediction
title_full_unstemmed Explainable deep drug–target representations for binding affinity prediction
title_short Explainable deep drug–target representations for binding affinity prediction
title_sort explainable deep drug–target representations for binding affinity prediction
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204982/
https://www.ncbi.nlm.nih.gov/pubmed/35715734
http://dx.doi.org/10.1186/s12859-022-04767-y
work_keys_str_mv AT monteironelsonrc explainabledeepdrugtargetrepresentationsforbindingaffinityprediction
AT simoescarlosjv explainabledeepdrugtargetrepresentationsforbindingaffinityprediction
AT avilahenriquev explainabledeepdrugtargetrepresentationsforbindingaffinityprediction
AT abbasimaryam explainabledeepdrugtargetrepresentationsforbindingaffinityprediction
AT oliveirajosel explainabledeepdrugtargetrepresentationsforbindingaffinityprediction
AT arraisjoelp explainabledeepdrugtargetrepresentationsforbindingaffinityprediction